Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
Regeneron (NASDAQ: REGN) will present at the 44th Annual J.P.
Rhea-AI Summary
Regeneron (NASDAQ: REGN) will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026.
The live webcast is scheduled for 2:15 p.m. Pacific Time / 5:15 p.m. Eastern Time and can be accessed from the company’s Investors & Media page at http://investor.regeneron.com/events-and-presentations. A replay and transcript will be archived on the company website for at least 30 days.
Positive
- None.
Negative
- None.
Details
News Market Reaction – REGN
On Dec 23, the first trading day after this news, REGN closed 0.75% above the previous close.
Data tracked by StockTitan Argus for the Dec 23 session.
Key Figures
- Conference edition
- 44th
- 44th Annual J.P. Morgan Healthcare Conference
- Presentation date
- January 12, 2026
- Scheduled conference presentation date
- Presentation time PT
- 2:15 p.m.
- Scheduled time in Pacific Time
- Presentation time ET
- 5:15 p.m.
- Scheduled time in Eastern Time
- Replay availability
- at least 30 days
- Replay and transcript archived on company website
Historical Context
-
Encouraging Phase 1/2 Lynozyfic NDMM data with high VGPR+ and MRD negativity.
-
Global TSRA-196 gene-editing partnership for AATD with upfront and milestones.
-
EU approval for Dupixent in CSU based on LIBERTY-CUPID Phase 3 data.
-
FDA approval of EYLEA HD 8 mg for RVO and broader monthly dosing option.
-
EU approval of Libtayo as first adjuvant immunotherapy for high-risk CSCC.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TARRYTOWN, N.Y., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. The presentation is scheduled for 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time) and may be accessed from the "Investors & Media" page of Regeneron's website at http://investor.regeneron.com/events-and-presentations. A replay and transcript of the webcast will be archived on the Company's website for at least 30 days.
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.
For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.
Contact Information:
Investor Relations
Ryan Crowe
914.847.8790
ryan.crowe@regeneron.com
Corporate Communications
Christina Chan
914.847.8827
christina.chan@regeneron.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.